S&P 500   3,605.40 (-0.91%)
DOW   29,519.32 (-1.31%)
QQQ   296.82 (-0.73%)
AAPL   117.99 (+1.20%)
MSFT   211.91 (-1.54%)
FB   273.18 (-1.67%)
GOOGL   1,754.38 (-1.83%)
AMZN   3,151.58 (-1.37%)
TSLA   578.44 (-1.25%)
NVDA   524.50 (-1.12%)
BABA   265.20 (-4.08%)
CGC   28.47 (-1.83%)
GE   10.25 (-1.44%)
MU   64.09 (-0.22%)
AMD   87.98 (+0.91%)
T   28.96 (-0.24%)
NIO   51.12 (-5.33%)
F   9.13 (+0.44%)
ACB   10.66 (+1.81%)
NFLX   484.31 (-1.43%)
BA   212.84 (-1.69%)
GILD   59.77 (-0.43%)
DIS   147.67 (+0.37%)
S&P 500   3,605.40 (-0.91%)
DOW   29,519.32 (-1.31%)
QQQ   296.82 (-0.73%)
AAPL   117.99 (+1.20%)
MSFT   211.91 (-1.54%)
FB   273.18 (-1.67%)
GOOGL   1,754.38 (-1.83%)
AMZN   3,151.58 (-1.37%)
TSLA   578.44 (-1.25%)
NVDA   524.50 (-1.12%)
BABA   265.20 (-4.08%)
CGC   28.47 (-1.83%)
GE   10.25 (-1.44%)
MU   64.09 (-0.22%)
AMD   87.98 (+0.91%)
T   28.96 (-0.24%)
NIO   51.12 (-5.33%)
F   9.13 (+0.44%)
ACB   10.66 (+1.81%)
NFLX   484.31 (-1.43%)
BA   212.84 (-1.69%)
GILD   59.77 (-0.43%)
DIS   147.67 (+0.37%)
S&P 500   3,605.40 (-0.91%)
DOW   29,519.32 (-1.31%)
QQQ   296.82 (-0.73%)
AAPL   117.99 (+1.20%)
MSFT   211.91 (-1.54%)
FB   273.18 (-1.67%)
GOOGL   1,754.38 (-1.83%)
AMZN   3,151.58 (-1.37%)
TSLA   578.44 (-1.25%)
NVDA   524.50 (-1.12%)
BABA   265.20 (-4.08%)
CGC   28.47 (-1.83%)
GE   10.25 (-1.44%)
MU   64.09 (-0.22%)
AMD   87.98 (+0.91%)
T   28.96 (-0.24%)
NIO   51.12 (-5.33%)
F   9.13 (+0.44%)
ACB   10.66 (+1.81%)
NFLX   484.31 (-1.43%)
BA   212.84 (-1.69%)
GILD   59.77 (-0.43%)
DIS   147.67 (+0.37%)
S&P 500   3,605.40 (-0.91%)
DOW   29,519.32 (-1.31%)
QQQ   296.82 (-0.73%)
AAPL   117.99 (+1.20%)
MSFT   211.91 (-1.54%)
FB   273.18 (-1.67%)
GOOGL   1,754.38 (-1.83%)
AMZN   3,151.58 (-1.37%)
TSLA   578.44 (-1.25%)
NVDA   524.50 (-1.12%)
BABA   265.20 (-4.08%)
CGC   28.47 (-1.83%)
GE   10.25 (-1.44%)
MU   64.09 (-0.22%)
AMD   87.98 (+0.91%)
T   28.96 (-0.24%)
NIO   51.12 (-5.33%)
F   9.13 (+0.44%)
ACB   10.66 (+1.81%)
NFLX   484.31 (-1.43%)
BA   212.84 (-1.69%)
GILD   59.77 (-0.43%)
DIS   147.67 (+0.37%)
Log in
NYSE:TAK

Takeda Pharmaceutical Stock Forecast, Price & News

$17.78
-0.19 (-1.06 %)
(As of 11/30/2020 11:10 AM ET)
Add
Compare
Today's Range
$17.78
Now: $17.78
$18.02
50-Day Range
$15.39
MA: $16.93
$17.89
52-Week Range
$12.43
Now: $17.78
$20.60
Volume14,013 shs
Average Volume1.27 million shs
Market Capitalization$56.06 billion
P/E Ratio39.51
Dividend Yield3.39%
Beta0.96
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, rest of Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with TESARO, Inc., Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Rani Therapeutics LLC, Novimmune S.A., AB Biosciences Inc., Sosei Group Corporation, and LogicBio Therapeutics, Inc.; strategic collaboration with Prometheus Biosciences, Inc; a license and research agreement with The University of Texas MD Anderson Cancer Center; a research collaboration agreements with Enzyre BV and Cerevance; a collaboration agreement with Artisan Bio, Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd., as well as licensing agreement with ProThera Biologics Inc. It also has a corporate strategic research alliance with Egle Therapeutics SAS to uncover novel tumor-specific regulatory t-cell targets and develop unique anti-suppressor-based immunotherapies; a strategic partnership with Neurocrine Biosciences, Inc. to develop and commercialize therapies for psychiatric disorders; and Carmine Therapeutics to discover, develop, and commercialize transformative non-viral gene therapies for two rare diseases. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.1Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.45 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone813-3278-2111
Employees47,495

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$30.20 billion
Cash Flow$3.67 per share
Book Value$13.80 per share

Profitability

Net Income$407.02 million

Miscellaneous

Outstanding Shares3,152,750,000
Market Cap$56.06 billion
Next Earnings Date2/2/2021 (Estimated)
OptionableOptionable
$17.78
-0.19 (-1.06 %)
(As of 11/30/2020 11:10 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TAK News and Ratings via Email

Sign-up to receive the latest news and ratings for TAK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Takeda Pharmaceutical (NYSE:TAK) Frequently Asked Questions

How has Takeda Pharmaceutical's stock price been impacted by Coronavirus?

Takeda Pharmaceutical's stock was trading at $17.15 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TAK stock has increased by 4.1% and is now trading at $17.86.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Takeda Pharmaceutical?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Takeda Pharmaceutical
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Takeda Pharmaceutical?

Wall Street analysts have given Takeda Pharmaceutical a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Takeda Pharmaceutical wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Takeda Pharmaceutical's next earnings date?

Takeda Pharmaceutical is scheduled to release its next quarterly earnings announcement on Tuesday, February 2nd 2021.
View our earnings forecast for Takeda Pharmaceutical
.

What price target have analysts set for TAK?

1 brokers have issued 12 month price objectives for Takeda Pharmaceutical's stock. Their forecasts range from $30.00 to $30.00. On average, they expect Takeda Pharmaceutical's stock price to reach $30.00 in the next twelve months. This suggests a possible upside of 68.0% from the stock's current price.
View analysts' price targets for Takeda Pharmaceutical
.

Are investors shorting Takeda Pharmaceutical?

Takeda Pharmaceutical saw a increase in short interest during the month of October. As of October 30th, there was short interest totaling 5,170,000 shares, an increase of 37.9% from the October 15th total of 3,750,000 shares. Based on an average daily trading volume, of 1,160,000 shares, the short-interest ratio is currently 4.5 days. Currently, 0.2% of the shares of the company are short sold.
View Takeda Pharmaceutical's Short Interest
.

Who are some of Takeda Pharmaceutical's key competitors?

What other stocks do shareholders of Takeda Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Cisco Systems (CSCO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Pfizer (PFE), Verizon Communications (VZ), AbbVie (ABBV), CVS Health (CVS), Gilead Sciences (GILD), AT&T (T) and Abbott Laboratories (ABT).

Who are Takeda Pharmaceutical's key executives?

Takeda Pharmaceutical's management team includes the following people:
  • Mr. Christophe Weber, Pres, CEO & Representative Director (Age 54)
  • Mr. Constantine Saroukos, CFO & Director (Age 49)
  • Mr. Masato Iwasaki, Pres of Japan Pharma Bus. Unit & Director (Age 62)
  • Dr. Andrew S. Plump, Pres of R&D and Director (Age 55)
  • Dr. Seigo Izumo, Chair of Management Board
  • Mr. Haruhiko Hirate, Member of Management Board (Age 63)
  • Salvatore Alesci, Member of Management Board and Head of R&D Global Science & Biomedical Policy
  • Mr. Iwaaki Taniguchi, Sr. VP of Corp. Fin. & Controlling Department
  • Takashi Okubo, Global Head of IR, Global Fin.
  • Mr. Yoshihiro Nakagawa, Global Gen. Counsel (Age 60)

What is Takeda Pharmaceutical's stock symbol?

Takeda Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "TAK."

Who are Takeda Pharmaceutical's major shareholders?

Takeda Pharmaceutical's stock is owned by many different retail and institutional investors. Top institutional investors include Adelphi Capital LLP (0.26%), Morgan Stanley (0.06%), Wells Fargo & Company MN (0.05%), Brandes Investment Partners LP (0.05%), Aperio Group LLC (0.04%) and ARK Investment Management LLC (0.04%).

Which major investors are selling Takeda Pharmaceutical stock?

TAK stock was sold by a variety of institutional investors in the last quarter, including Adelphi Capital LLP, TD Asset Management Inc., Brandes Investment Partners LP, CIBC Asset Management Inc, Arrowstreet Capital Limited Partnership, Raymond James & Associates, Pinnacle Associates Ltd., and Avalon Investment & Advisory.

Which major investors are buying Takeda Pharmaceutical stock?

TAK stock was bought by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Wells Fargo & Company MN, Managed Asset Portfolios LLC, Aperio Group LLC, Mizuho Securities Co. Ltd., JCIC Asset Management Inc., OLD Mission Capital LLC, and JPMorgan Chase & Co..

How do I buy shares of Takeda Pharmaceutical?

Shares of TAK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Takeda Pharmaceutical's stock price today?

One share of TAK stock can currently be purchased for approximately $17.86.

How big of a company is Takeda Pharmaceutical?

Takeda Pharmaceutical has a market capitalization of $56.31 billion and generates $30.20 billion in revenue each year. The company earns $407.02 million in net income (profit) each year or $1.78 on an earnings per share basis. Takeda Pharmaceutical employs 47,495 workers across the globe.

What is Takeda Pharmaceutical's official website?

The official website for Takeda Pharmaceutical is www.takeda.com.

How can I contact Takeda Pharmaceutical?

Takeda Pharmaceutical's mailing address is 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0, 103-8668. The company can be reached via phone at 813-3278-2111.

This page was last updated on 11/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.